Fig. 1.
Acute treatment with the M1PAM VU846 at 3 mg/kg improved AEP in RTT mice. A. Grand average AEP in wildtype (WT, n = 11) animals 30 min after acute injection of vehicle (gray) or 3 mg/kg VU846 (yellow), showing no change in AEP after VU846 injection. B. Grand average AEP in Mecp2+/− mice (n = 11) after vehicle (black) or 3 mg/kg VU846 (purple) injection, showing increased N1 and P2 amplitudes. C. Individual WT animal AEP peak amplitudes after vehicle or VU846 injection. D. Individual MUT animal peak amplitudes after vehicle or VU846 injection. 3 mg/kg VU846 treatment increased N1, P2 and N1–P2 amplitudes in MUT mice (∗p < 0.05, paired t-test). E. P2 rising slope in WT and MUT animals after vehicle or 3 mg/kg VU846 injection. P2 rising slope was reduced in MUT animals compared to WT after vehicle injection but increased after VU846 injection. F. P2 decay slope in WT and MUT animals after vehicle or 3 mg/kg VU846 injection. P2 decay slope was decreased in vehicle treated MUT animals but increased to WT levels after VU846 injection. (E and F, ∗p < 0.05 and ∗∗p < 0.01 one-way ANOVA followed by posthoc Tukey's multiple comparisons test). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article).